Gastric Cancer Marker Detection and Its Kit Development
Second Affiliated Hospital of Wenzhou Medical University
530 participants
Jan 1, 2021
OBSERVATIONAL
Conditions
Summary
The gastric cancer diagnosis and treatment specifications clearly point out that tumor markers need to be detected in the process of diagnosis, efficacy evaluation and follow-up. However, there is currently a lack of gastric cancer markers with high sensitivity and specificity, and the detection of markers is limited to a single index analysis, which has many shortcomings such as long analysis time, large reagent consumption, and high detection cost. Therefore, this project will use protein chips to detect new types of gastric cancer patient markers and establish a multi-diagnostic model for early screening of gastric cancer. Finally, monoclonal antibodies will be produced against various high-specific tumor markers and a gastric cancer diagnostic kit will be established.
Eligibility
Inclusion Criteria11
- patient
- Age is greater than or equal to 18 years old (including 18 years old);
- Patients who are diagnosed with cancer after pathological diagnosis;
- Can provide enough tissue samples;
- Have not received anti-tumor treatment in the past;
- Comply with the principle of informed consent and sign the informed consent form.
- healthy person:
- Age is greater than or equal to 18 years old (including 18 years old);
- No underlying disease;
- Can provide enough tissue samples;
- Comply with the principle of informed consent and sign the informed consent form.
Exclusion Criteria7
- The tumor foci cannot be clearly derived from a specific tumor type;
- Those who have a history of other tumors, autoimmune diseases and allergies;
- Previously received anti-tumor treatments such as surgery, chemotherapy, radiotherapy, molecular targeted therapy, immunotherapy, biological therapy or Chinese medicines with anti-cancer and anti-tumor effects in the instructions;
- Participated in any clinical trial within 90 days before the experiment;
- Received major surgery within 90 days before the experiment;
- Received bone marrow transplantation 90 days before the experiment;
- Subjects who may not be able to complete the study due to other reasons or who are determined by the investigator to be unsuitable to participate in this study.
Interventions
The subject will be drawn a 5ml blood sample
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05010863